Thomas Videbaek
Chairman en Protera SAS .
Perfil
El Dr. Thomas Videbaek es presidente de Protera SAS, director no ejecutivo independiente de Camlin Fine Sciences Ltd. y director general de Novozymes BioloAg A/S. Forma parte del Consejo de Administración de Camlin Fine Sciences Ltd., Novozymes Biopharma DK A/S, Evolva SA y Albumedix A/S. Anteriormente, el Dr. Videbaek fue director no ejecutivo de Evolva Holding SA, vicepresidente ejecutivo de Personas, Sostenibilidad y Marca de Novozymes A/S, vicepresidente de Marketing de Cereales y Bebidas de Novozymes Switzerland AG y director de Marketing Estratégico de Novo Nordisk A/S. También formó parte del consejo de administración de Novozymes BioAg Group y Beta Renewables SpA. Se licenció en la Escuela de Negocios de Copenhague, se graduó en la Universidad Técnica de Dinamarca y se doctoró en la Universidad Técnica de Dinamarca.
Cargos activos de Thomas Videbaek
Empresas | Cargo | Inicio |
---|---|---|
Albumedix A/S
Albumedix A/S Pharmaceuticals: MajorHealth Technology Albumedix A/S is a Danish biotechnology company. The private company is based in Copenhagen, Denmark. | Director/Board Member | - |
Novozymes Biopharma DK A/S
Novozymes Biopharma DK A/S Pharmaceuticals: MajorHealth Technology Novozymes Biopharma DK A/S engages in the wholesale of pharmaceuticals and medical article. The firm operates and invests in research, development, production, and trade in biological solutions, including pharmaceuticals, and biotechnology products and processes.The company was founded on May 29, 2006 and is headquartered in Bagsvaerd, Denmark. | Director/Board Member | - |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Director/Board Member | - |
Protera SAS
Protera SAS Food: Major DiversifiedConsumer Non-Durables Protera SAS manufactures protein-based ingredients to address critical challenges in food, agriculture, the environment, and human health. Its products include Guard, Sense, antioxidant proteins, and foaming and emulsifying proteins. The company was founded by Leonardo Álvarez and Francia Navarrete and is headquartered in Neuilly-sur-Seine, France. | Chairman | 06/04/2021 |
Evolva AG | Director/Board Member | - |
Enduro Genetics ApS
Enduro Genetics ApS Miscellaneous Commercial ServicesCommercial Services Enduro Genetics ApS is a Danish biotechnology research company that specializes in developing bio products. The company is based in Copenhagen, Denmark. Enduro Genetics was founded by Peter Rugbjerg and Christian Munck. The CEO is Christian Munch. | Director/Board Member | - |
Antiguos cargos conocidos de Thomas Videbaek.
Empresas | Cargo | Fin |
---|---|---|
CAMLIN FINE SCIENCES LIMITED | Director/Board Member | 23/02/2023 |
EVOLVA HOLDING SA | Director/Board Member | 15/04/2020 |
Novozymes Switzerland AG | Corporate Officer/Principal | 01/01/2003 |
░░░░░░░░░ ░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formación de Thomas Videbaek.
Copenhagen Business School | Undergraduate Degree |
Technical University of Denmark | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
NOVO NORDISK A/S | Health Technology |
CAMLIN FINE SCIENCES LIMITED | Process Industries |
EVOLVA HOLDING SA | Consumer Non-Durables |
Empresas privadas | 11 |
---|---|
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Process Industries |
Novozymes BioAg Group
Novozymes BioAg Group BiotechnologyHealth Technology Novozymes BioAg Group was developed and manufactured microbial products. The company was founded in 1980 and was headquartered in Saskatoon, Canada. | Health Technology |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Commercial Services |
Novozymes BioloAg A/S
Novozymes BioloAg A/S BiotechnologyHealth Technology Novozymes BioloAg A/S provides research and development for biotechnology products and processes. It participates in The BioAg Alliance to commercialize BioAg assets and competencies within microbial research, development, and production. The company was founded on October 22, 2007 and is headquartered in Bagsvaerd, Denmark. | Health Technology |
Novozymes Biopharma DK A/S
Novozymes Biopharma DK A/S Pharmaceuticals: MajorHealth Technology Novozymes Biopharma DK A/S engages in the wholesale of pharmaceuticals and medical article. The firm operates and invests in research, development, production, and trade in biological solutions, including pharmaceuticals, and biotechnology products and processes.The company was founded on May 29, 2006 and is headquartered in Bagsvaerd, Denmark. | Health Technology |
Novozymes Switzerland AG | |
Beta Renewables SpA
Beta Renewables SpA Chemicals: Major DiversifiedProcess Industries Beta Renewables SpA develops bio fuels and biochemical compounds. The company was founded in 2011 and is headquartered in Tortona, Italy. | Process Industries |
Albumedix A/S
Albumedix A/S Pharmaceuticals: MajorHealth Technology Albumedix A/S is a Danish biotechnology company. The private company is based in Copenhagen, Denmark. | Health Technology |
Evolva AG | |
Protera SAS
Protera SAS Food: Major DiversifiedConsumer Non-Durables Protera SAS manufactures protein-based ingredients to address critical challenges in food, agriculture, the environment, and human health. Its products include Guard, Sense, antioxidant proteins, and foaming and emulsifying proteins. The company was founded by Leonardo Álvarez and Francia Navarrete and is headquartered in Neuilly-sur-Seine, France. | Consumer Non-Durables |
Enduro Genetics ApS
Enduro Genetics ApS Miscellaneous Commercial ServicesCommercial Services Enduro Genetics ApS is a Danish biotechnology research company that specializes in developing bio products. The company is based in Copenhagen, Denmark. Enduro Genetics was founded by Peter Rugbjerg and Christian Munck. The CEO is Christian Munch. | Commercial Services |
- Bolsa de valores
- Insiders
- Thomas Videbaek